ASCO 2016 Ovarian Cancer ( 3 articles 1 author) Cancer Network

Cancer Network
 ASCO 2016 Ovarian Cancer, Gynecologic Cancers, Ovarian Cancer

• IP Carboplatin/IV Paclitaxel Promising in Ovarian, Peritoneal Cancer

Bryant Furlow

June 09, 2016 

 

Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

• Baseline QoL Can Predict Survival in Platinum-Resistant Ovarian Cancer

Bryant Furlow

June 08, 2016 

 

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.

• Extending Platinum-Free Interval Might Reduce Survival in Recurrent Ovarian Cancer

Bryant Furlow

June 08, 2016 

 

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.